Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (11 issues)
Up 1.38%, with healthcare distribution benefiting from the sector rotation (XLV +2.36%). 21 analysts target $255.60 for 9.9% upside amid bullish moving-average alignment — continue holding
Position: +2.5% in the drug-distribution cash machine, 7% off the high, hold
Steady drug-distribution cash flows 6.6% off the high with 21 analysts at +12% — hold
Flat-ish, -0.09% at $228.5. TD Cowen lifts to $275, BofA to $260, full-year EPS guide already raised. Coiling into the 8/11 print — stay long.
Up 1.7% to $228.72 as drug distribution joins the old-economy healthcare counterattack; holding
Down 2.3% to $224.94 in the healthcare giveback (Elevance shrapnel) — structure intact above the 50-day; holding
Down 0.9% to $233.66 — normal noise near the highs; the drug-distribution slow bull holds
Up 0.9%, back at 52-week highs; the drug-distribution slow bull is open for business as usual — holding
Down 1.4%, a second breather at the highs; giving back after a 15% month doesn't bend the trend — the 20-day ($231) is the line
Down 1.1% — the first breather after 52-week highs; up 17% on the month, any dip is generosity, holding
+0.9% to fresh 52-week highs, +18% month; drug distribution with defense and momentum